Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644 1645 1656 1675 1677
This examiner grants 86% of resolved cases
Amelia Carole Stephens is an examiner in Tech Center 1600 and Art Unit 1644. The examiner has 7 resolved cases in the current data set. The allowance rate is 85.7 percent, which indicates that a majority of applications reach issuance. This percentage provides a baseline for practitioners to evaluate the probability of a grant when assigned to this specific examiner.
The interview lift is 33.3 percent. This significant lift indicates that conducting an interview with the examiner correlates with a much higher likelihood of securing an allowance. Practitioners can use this 33.3 percent figure to justify the resources spent on direct communication, as it represents a measurable improvement in the probability of success. This impact is a notable feature of the examiner's historical data.
The median time to allowance is 1020 days. This duration represents the typical timeframe for successful applications to move from filing to issuance. With 7 resolved cases as the basis for these metrics, the profile provides an indication of the timeline and success rates expected in Art Unit 1644. These figures help practitioners manage expectations regarding the duration of the process in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18290730 | DE-CLUSTERING INHIBITORS OF PTPRA | Non-Final OA | The Regents of the University of California |
| 18248436 | COMPOSITIONS AND METHODS INVOLVING ANTIBODY CONSTRUCTS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 19066479 | CWP2 PROTEIN AS AN EFFECTIVE VACCINE AGAINST CLOSTRIDIOIDES DIFFICILE INFECTION | Non-Final OA | UNIVERSITY OF SOUTH FLORIDA |
| 18928711 | COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE COMPRISING PHOSPHOLIPASE C ACTIVATOR AS AN ACTIVE INGREDIENT | Non-Final OA | Korea University Research and Business Foundation |
| 18687542 | PEPTIDE FOR DETECTING CA125 AND USE THEREOF | Non-Final OA | Ajou University Industry-Academic Cooperation Foundation |
| 18519225 | COMBINED USE OF UBENIMEX AND IMMUNE CHECKPOINT INHIBITOR | Final Rejection | NIPPON KAYAKU KABUSHIKI KAISHA |
| 18265405 | ANTI-EGFR CHIMERIC ANTIGEN RECEPTORS | Non-Final OA | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 18044195 | IMMUNOTHERAPY COMPOSITION | Non-Final OA | GAMMADELTA THERAPEUTICS LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy